Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say.
Neffy, a needle-free epinephrine nasal spray, showed promise as a safe alternative for treating anaphylaxis in children with food allergies in a phase 3 trial.
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.